A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants

Project: Other project

StatusActive
Effective start/end date7/2/187/1/20

Funding

  • Merck Sharp & Dohme Corporation: $19,459.76